ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE | VIIV HLTHCARE | ||
EQ 300MG BASE;150MG;300MG | |||
Yes | No | ||
2018-Nov-14 | Expired | ||
None | None | ||
None | No | ||
TRIZIVIR, a combination of abacavir, lamivudine, and zidovudine, each nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. |
1 | 1 | 1 |
Total Other Developers | 1 |
---|
Drugs with Suitability | No |
---|
EQ 300MG BASE;150MG;300MG | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 1 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|---|---|---|---|---|
****** | ***** *** | ***** ******* | *********** | ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) | *** |
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com